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dissection.
Methods: From January 1998 to March 2004, 29 patients (7 women and 22 men) with acute complicated aortic
type B dissection (mean age, 61 years; range, 22–78), defined as aortic rupture, malperfusion, intractable pain, or
uncontrolled hypertension, underwent endovascular stent graft placement with the Medtronic Talent device.
Five patients (17%) had undergone previous surgery on the ascending aorta and/or aortic valve. The mean aortic
diameter at intervention was 48  13 mm. Follow-up was 100% complete and averaged 53  41 months.
Results: The technical feasibility and success with deployment proximal to the entry tear was 100%, requiring
partial or total coverage of the left subclavian artery in only 1 patient (3%). Hospital mortality was 17% 7%
(70% confidence limit) with 6 late deaths. The causes of hospital death included multiorgan failure in 2 patients,
aortic rupture in 2, and retrograde dissection in 1 patient. Three patients (10%) who survived the procedure de-
veloped neurologic complications (2 strokes and 1 transient ischemic attack). One patient required early conver-
sion to surgery because of retrograde type A dissection. Furthermore, 4 patients developed a type Ia endoleak. A
postprocedural increase in the distal aortic diameter was observed in 3 patients. The actuarial survival at 1 and 5
years was 79% and 61%, respectively. Freedom from treatment failure at 1 and 5 years (including reinterven-
tion, aortic rupture, device-related complications, aortic-related death, or sudden, unexplained late death) was
82% and 77%, respectively.
Conclusions: Endovascular stent graft placement in acute complicated type B aortic dissection proves to be
a promising alternative therapeutic treatment modality in this relatively difficult patient cohort. Refinements,
especially in stent design and application, could further improve the prognosis of patients in this life-
threatening situation. (J Thorac Cardiovasc Surg 2013;145:159-65)Acute aortic dissection of the descending aorta is still a life-
threatening condition with high mortality and morbidity
and remains a formidable challenge for cardiac surgeons,
as well as, in recent years, interventional radiologists. The
optimal management of these patients remains a matter of
ongoing debate.1,2 In cases of uncomplicated aortic type
B dissection, medical treatment controlling hypertension
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The Journal of Thoracic and Catreatment option.3 Conventional resection and graft replace-
ment of the descending thoracic aorta has been the preferred
method of treatment only in cases with complications such
as aortic rupture, malperfusion of end organs, and/or persis-
tent pain despite medical treatment but was associated
with high morbidity and mortality rates despite improved
surgical techniques, intraoperative monitoring of somato-
sensory evoked potentials and spinal fluid drainage.4,5
Contemporary mortality rates after surgical resection of
acute complicated type B dissection range from 15% to
30% and even exceed 50% in complicated cases under
emergency conditions.6 Furthermore, the afflicted popula-
tion is usually older age and present to surgery with various
comorbidities, such as hypertension, obstructive pulmonary
disease, and coronary heart disease, all of which have
significant effects on the surgical outcome. In the past 2 de-
cades, many groups have started to investigate the feasibil-
ity of thoracic aortic aneurysmal repair with endovascular
stent grafts for various aortic pathologic conditions.7-10
During the past decade, endovascular techniques have
revolutionized the management of descending thoracic
aortic disease, with the benefit of the exclusion of the
pathologically altered aorta without direct surgicalrdiovascular Surgery c Volume 145, Number 1 159
Abbreviation and Acronym
TTR ¼ Talent Thoracic Registry
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an attractive and safer alternative approach for treating such
special aortic pathologic conditions such as complicated
acute type B dissections.11 The Talent Thoracic Registry
(TTR) was designed to collect outcomes data from patients
who underwent endoluminal treatment with the Medtronic
Talent thoracic stent graft (Medtronic/AVE, Santa Rosa,
Calif) in 7 European referral centers, and the short-term re-
sults were reported.12 The present subanalysis of the TTR
comprises only data from patients who underwent endovas-
cular stent graft placement for acute complicated type B
aortic dissections.
METHODS
Enrollment
The present analysis from the TTR registry focused on 29 consecutive
patients (7 women and 22 men) with acute complicated aortic type B dis-
section (mean age, 61 years; range, 22–78), defined as aortic rupture, mal-
perfusion, intractable pain, or uncontrolled hypertension who underwent
endovascular repair with the Talent Thoracic stent graft from November
1996 toMarch 2004. This subgroup represents 6% from a total of 457 cases
with thoracic aortic pathologic features collected for the TTR registry.
Seven European referral centers (Bologna, Italy; Lille, France; Marseille,
France; Nieuwegein, The Netherlands; Rostock, Germany, Toulouse,
France; and Vienna, Austria) provided data from patients treated consecu-
tively, with a minimum of 1 year of follow-up. The TTR was approved by
the local ethical committee of each participant center. Follow-up analysis
was formed on clinical and imaging findings until the last visit and included
all adverse events. Data were collected on case report forms and checked
for inconsistencies. In the case of discrepancies, the attending investigator
was queried to ensure appropriate interpretation of the events.
Patient Characteristics
An American Society of Anesthesiologists classification greater than
class IV was present in 72% of all cases (Table 1). Five patients (17%)
had undergone previous aortic surgery. Comorbid medical conditions in-
cluded hypertension in 25 (86%), coronary artery disease in 8 (27%),
and chronic obstructive pulmonary disease in 4 (14%). One of the treated
patients had Marfan syndrome.
In 7 patients (24%), the dissections extended only into the descending
aorta, in 5 patients (17%) to the celiac axes, in 5 (17%) into the aortic bi-
furcation, and in 12 patients (41%) into the iliac arteries (Table 2). The in-
dication for stent graft placement was persistent ongoing pain for longer
than 72 hours despite aggressive pain medication in 5 patients, refractory
hypertension in 2 patients, rupture in 5 patients, and malperfusion in 17
patients (Table 2).
Device Description
The Talent Thoracic stent graft is composed of Dacron graft fabric sup-
ported by self-expanding nitinol springs. The springs are sewn to the graft
material with polyester sutures. The graft material is a sheet of monofila-
ment polyester with a seam joining the edges to create a cylindrical tube.
The connecting bar provides columnar strength to the device and facilitates
deployment. All Talent stent grafts in the study had uncovered springs
proximally, and the smallest graft size was 22 mm.160 The Journal of Thoracic and Cardiovascular SurgPreintervention Imaging
Before endovascular treatment, all patients were examined by at least
1 tomographic imaging modality (Figure 1). Computed tomography or
magnetic resonance imaging was preferred. In some specific cases, angiog-
raphy or transesophageal echocardiography was also performed. Contrast-
enhanced computed tomography was the most frequently used diagnostic
method (95%), followed by angiography (37%), transesophageal echocar-
diography (17%), and magnetic resonance imaging (5%). All operations
were performed with the patient under general anesthesia in the radiology
suite under fluoroscopy control by a C-arm image intensifier. The technique
of stent graft insertion has been previously reported.12
Definitions
Procedural success was defined as successful deployment of the stent
graft device. Primary success was defined as complete exclusion of the
injured side without any additional intervention. Secondary success was
defined as complete exclusion of the aneurysm after secondary interven-
tion. An endoleak was defined as radiologic evidence of blood flow outside
the stent graft and was classified as primary (diagnosed within 30 days of
endovascular repair) or secondary (diagnosed more than 30 days after in-
tervention). Malperfusion was defined as radiologic signs of hypoperfusion
in the visceral region, renal arteries, lower extremities. The following were
also considered symptoms of malperfusion: clinical signs of an acute
abdomen, lactic acidosis, oliguria or aneuria, increasing values on renal
functions tests, abnormal pulse examination, paresthesia, or paralysis.
Statistical Analysis
Continuous data are presented as the median and interquartile range
(25th to 75th percentiles). Discrete data are given as counts and percent-
ages. Time-dependent Cox regression analysis was performed to assess
the potential risk factors on overall outcome. Only preoperative variables
were considered for inclusion in the model based on the rationale of a pre-
operative risk assessment. The results of the regression model are given as
the odds ratio and 95% confidence intervals. Regression diagnostics and
overall model fit were performed according to standard procedures. Calcu-
lations were performed using the Statistical Package for Social Sciences,
for Mac OsX, version 16.0 (SPSS, Chicago, Ill).RESULTS
In-Hospital Results
Technical feasibility with deployment of the stent graft
device at the targeted position was 100% (Figure 2). Pri-
mary success was achieved in 23 (85%) of 27 patients.
Four patients developed an early type Ia endoleak (15%).
One underwent conversion to conventional surgery because
no additional interventional option was possible. Two other
patients had proximal stent graft extension with sealing of
the endoleak site in 1 patient. The fourth patient had under-
gone stent graft placement in an emergency setting with
malperfusion of the visceral organs. Decompression of the
true lumen was achieved but the patient had a type 1a endo-
leak. Owing to his problematic conditions, no additional
intervention was made, and the patient is now under surveil-
lance with no additional increase in the aortic diameter. The
rate of persistent primary endoleak was 8% (Table 3). Ves-
sel access was achieved through the left or right common
femoral artery in all patients. The mean aortic diameter at
intervention was 48  13 mm and the mean covered length
of the descending aorta was 140  47 mm. Of the 29ery c January 2013
TABLE 1. Demographics and clinical characteristics (n ¼ 29)
Variable Value
Men 22 (76)
Age (yr)
Mean 61
Range 22-78
Comorbidity
Hypertension 25 (86)
Marfan syndrome 1 (3)
COPD 4 (14)
Coronary artery disease 8 (27)
Diabetes 4 (14)
Previous aortic surgery 5 (17)
ASA score>IV 21 (72)
Data presented as number of patients, with percentages in parentheses, unless other-
wise noted. COPD, Chronic obstructive pulmonary disease; ASA, American Society
of Anesthesiologists.
FIGURE 1. Preoperative computed tomography scan of a malperfusion
syndrome due to acute complicated type B dissection.
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and 1 with 3 (Table 3). The left subclavian artery was inten-
tionally totally covered by the stent graft in 1 patient (3%).
No symptoms of ischemia of the left arm or subclavian steal
syndrome requiring secondary revascularization were iden-
tified during the initial hospitalization.
A total of 17 patients presented with signs of malperfu-
sion. Of these, 8 patients had malperfusion of the renal ar-
teries, 5 had malperfusion of the lower extremity, and 4
had malperfusion of the celiac trunk or superior mesenteric
artery. Additional intraprocedural stenting was necessary in
6 patients to alleviate persistent obstruction of the true
lumen by extension of the intimal flap beyond the vessel’s
origin. Three patients required stenting of the celiac trunk,
two of the superior mesenteric artery, and one of the left
renal artery.
The overall hospital mortality was 17%  7% (95%
confidence interval) with 2 intraprocedural deaths from aor-
tic rupture and retrograde dissection into the ascending
aorta. The causes of the remaining 3 hospital deaths in-
cluded multiorgan failure in 2 patients and aortic rupture
in 1 patient. The 2 patients who died of multiorgan failure
had additional intraprocedural stenting of the superior mes-
enteric artery. Malperfusion, however, persisted with signsTABLE 2. Indication for intervention and extent of dissection (n¼ 29)
Indication for intervention Patients (n)
Malperfusion 17 (59)
Aortic rupture 5 (17)
Persistent ongoing pain 5 (17)
Refractory hypertension 2 (7)
Extent of dissection
Descending only 7 (24)
Descending to celiac axes 5 (17)
Descending to aortic bifurcation 5 (17)
Descending to iliac arteries 12 (42)
Data in parentheses are percentages.
The Journal of Thoracic and Caof bowel necrosis. After multisegmental bowel resection,
both patients died during their hospital stay. None of the
treated patients whowere younger than 52 years died during
the hospital stay and had a 1- and 5-year survival rate of
100% and 87%, respectively. In contrast, patients older
than 72 years had a hospital mortality rate of 29% with
worse long-term outcomes (Figure 4). Local injury with
reconstruction of the femoral artery was observed in 2
patients (7%).
Three patients (11%) developed new neurologic compli-
cations (2 strokes and 1 transient ischemic attack).Follow-Up
The mean follow-up period for hospital survivors was 53
 41 months, with an overall mortality rate of 25% (6/24
patients). Of the 6 late deaths, 2 (8%) were aortic relatedrdiovascular Surgery c Volume 145, Number 1 161
FIGURE 2. Postinterventional computed tomography scan.
FIGURE 3. Overall survival.
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The actuarial survival at 1 and 5 years was 79% and
61%, respectively (Figure 3). Two patients who survived
the procedure developed a late endoleak and both were suc-
cessfully treated by additional stent graft extensions. Free-
dom from treatment failure at 1 and 5 years (includingTABLE 3. Intraprocedural results (n ¼ 29)
Variable Value
Length of covered aorta (mm) 140  47
Distance from left subclavian artery
to stent (mm)
44  14
Stent grafts used (n)
1 19 (65)
2 9 (32)
3 1 (3)
Data presented as mean standard deviation or numbers of patients, with percentages
in parentheses.
162 The Journal of Thoracic and Cardiovascular Surgreintervention, aortic rupture, device-related complication,
aortic-related death, or sudden, unexplained late death)
was 82% and 77%, respectively (Figure 5). From the latest
computed tomography scan, complete thrombosis of the
false lumen just distally of the stent graft was observed in
62% of all surviving patients and partial or patent false lu-
men was seen in 21% and 17% of the remaining cases, re-
spectively. Additionally, in the 15 patients with complete
thrombosis of the false lumen, the mean false lumen diam-
eter between the first and last follow-up examination de-
creased in 8 patients (54%), was stable in 5 (33%), and
increased slightly in 2 (13%). In contrast, the false lumen
increased in 3 patients (60%) and remained stable in 2 pa-
tients (40%), in whom the false lumen was partially patent.
In those 4 patients, in whom the false lumen was fully pat-
ent, the diameter increased in 2 patients (50%), remained
stable in 1 (25%), and increased in 1 patient (25%).FIGURE 4. Overall survival according to age.
ery c January 2013
TABLE 4. Causes of late mortality
Cause Patients (n)
Aortic related
Aortic rupture 2 (8)
Nonaortic related
Bronchial carcinoma 1 (4)
Stroke 1 (4)
Myocardial infarction 1 (4)
Pneumonia 1 (4)
Data in parentheses are percentages.
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Transluminal placement of endovascular stent grafts has
been used in the past 2 decades as a treatment of descending
thoracic aortic pathologic findings such as degenerative an-
eurysm, acute or chronic dissection, and penetrating ulcer
or intramural hematoma.7,12 This innovative treatment
modality has gained increased acceptance across the
world, with excellent short-term results, and offers the pos-
sibility of treating patients who are not candidates for con-
ventional surgical procedures because of their existing
comorbidities. Furthermore, progress has been achieved
with regard to the safety and effectiveness of stent grafts
in the repair of thoracic aneurysms.10
Since the first reports describing the treatment of acute type
B aortic dissection with stent graft technology, optimism was
raised for improved early and late survival.13,14 The concept
of this procedure was directed toward sealing of the
proximal intimal tear, redirecting flow into the true lumen,
and promoting depressurization and thrombosis of the false
lumen. In addition, such an approach can effectively treat
malperfusion syndrome by reestablishing side branch flow in
dynamic obstruction.15,16 Furthermore, the primary stent
graft procedure might be used as a bridge to conventional
surgery, once the patient’s renal and hepatic problems haveFIGURE 5. Freedom from treatment failure.
The Journal of Thoracic and Caresolved and bowel ischemia has been reversed. Increasing
experience with endovascular treatment in the spectrum of
aortic dissection has confirmed both the feasibility and the
usefulness, especially in unstable patients, with encouraging
early and midterm results.17
Our results have indicated that stent graft placement is
a feasible and effective approach in the treatment of acute
complicated type B dissection. Most recent published reports
contain both complicated and uncomplicated cases, aswell as
mixed cases of acute and chronic dissection.18-22 However, it
was well demonstrated recently that controlling hypertension
and pain in the initial phase is the optimal approach for the
treatment of uncomplicated aortic type B dissection.3 There-
fore, in patients with life-threatening complications of acute
type B dissection, stent graft placement could emerge as
the most valid treatment option with the primary goal of alle-
viating severe malperfusion complications and aortic rupture
and stabilizing the patient in the first phase.
Hospital mortality in our series was 17%, similar to pub-
lished reports with a range of 3% to 20%.17,19,23 This
mortality rate corresponds to the reported mortality for
medically treated patients in historic controls and is better
than the expected open surgical mortality for these patients.
Effectively, endovascular techniques have shifted these
patients from the greater mortality associated with
complicated dissection treated surgically to lower mortality.
Nienaber and colleagues13 even reported in 1999 an early
mortality of 0% for 12 patients with descending aortic
aneurysm.However, in their series, the patient profiles and se-
lection were different. Endovascular stent grafting was not
performed as an emergency treatment in a life-threatening
situation. This might explain in part the difference in mortal-
ity. Nevertheless, the 3 stent graft-related deaths have demon-
strated the difficulties of conforming the device to the
curvature of the aortic arch. Although some improvements
have been seenwithmore recent generations of the endopros-
thesis, this problem still escapes solution. Additional techno-
logical developments are needed to obtain a stent graft that
aligns well in the arch and provides good fixation without
traumatizing the friable aortic wall.
Another important aspect in this clinical setting is that
stent graft placement over the intimal tear can prevent the
development of an aneurysm by facilitating complete
thrombosis of the false lumen. Therefore, to achieve satis-
factory mid- and long-term outcomes, the distance between
the left subclavian artery and the primary intimal entry tear
is important. If there is a sufficient ‘‘landing zone’’ and full
coverage of the proximal intimal tear can be achieved with
the stent graft, full thrombosis of the false lumen at the level
of the stent graft device can be expected. In contrast, if the
proximal intimal tear is very close to the left subclavian ar-
tery and the stent graft needs to be placed in the distal aortic
arch with coverage of the left subclavian artery, the risk of
a type 1a endoleak developing is increased. Furthermore,rdiovascular Surgery c Volume 145, Number 1 163
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by either erosion of the arterial wall or failure of the prox-
imal seal provided by the stent graft. Moreover, the mis-
alignment of stent grafts in angulated aortic arches,
together with the high hemodynamic forces in this region,
can cause structural instability of the stent graft and its sub-
sequent collapse.24 In the present series, the mean distance
between the left subclavian artery and the first stent graft
was 44 mm, reflecting a sufficient ‘‘landing zone’’ in
most of the treated patients.
Neurologic complications, especially paraplegia, remain
the most devastating complications after stent graft place-
ment or surgical repair of type B aortic dissection. Occlu-
sion of numerous critical intercostal arteries with stent
grafts is widely believed to be responsible for the increased
risk of paraplegia. The present study has shown that the
overall risk of neurologic complications in patients treated
with stent grafting was 11%, with none developing paraple-
gia. In addition, our data have demonstrated that stroke oc-
curred in 7% of the patients after stent graft treatment,
significantly greater than that reported in other series.17
We believe this was related to the older age of the patients
who developed this complication (75 and 78 years) and the
difficult advancement and manipulation of the guidewire or
stent graft delivery system within the aortic arch.
Complete thrombosis of the false lumen distally to the
stent graft was observed in 61% of our patients. This is
a rate consistent with the findings from other studies that re-
ported a rate of false lumen thrombosis in that region of
60% to 70%.25,26 Also, a significant reduction of the
false lumen diameter was achieved in these patients.
The rate of primary endoleaks after endovascular repair
of variant thoracic aortic lesions was reported to be 11%
to 20%.27,28 In our patient group, the rate of primary
endoleak was 15%. With additional proximal stent graft
extension and 1 surgical conversion, the rate of persistent
primary endoleak decreased to 8%. Overall, during the
follow-up period, an additional endovascular procedure
was performed successfully in 2 of 24 patients with persis-
tent primary endoleak.
The present review had some limitations. Because of its
retrospective nature, there was no control over the inclusion
criteria for the endovascular procedure. The lack of a ran-
domized or concurrent control group precluded direct com-
parison with conventional open repair or exclusive medical
therapy. In addition, to make any significant conclusions re-
garding the durability of endovascular therapy, it will be
necessary to obtain longer term follow-up data. The cur-
rently available data on follow-up outcomes fail to provide
precise morphologic information and, instead, focused on
clinical endpoints. Therefore, additional investigation is
crucial to assess the applicability and prognostic potential
of acute stent graft placement in patients with complicated
thoracic aortic dissection.164 The Journal of Thoracic and Cardiovascular SurgIn conclusion, endovascular treatment of thoracic aortic
disease with the Talent stent graft performed at high-
volume referral centers is associated with acceptable early
morbidity and mortality rates in this high-risk patient pop-
ulation. Most of all, closure of the entry tear and stabiliza-
tion of the true lumen presents a promising alternative
treatment option to conventional surgery for relief of life-
threatening dissection-related complications. Follow-up
data indicate a substantial durability of the procedure with
an acceptable freedom from stent graft-related death and
secondary interventions. Although preliminary data suggest
that stent graft repair might ultimately become the treat-
ment of choice for these relatively ill patients, long-term
surveillance will be crucial to discover the complications
unique to thoracic endovascular interventions. Most impor-
tantly, comparative clinical trials are clearly needed to clar-
ify the role of stent graft repair in the setting of acute
complicated type B aortic dissection.References
1. Erbel R, Alfonso F, Boileau C, Dirsch O, Eber B, Haverich A, et al., Task Force
on Aortic Dissection, European Society of Cardiology. Diagnosis and manage-
ment of aortic dissection. Eur Heart J. 2001;22:1642-81.
2. Nienaber CA, Eagle KA. Aortic dissection: new frontiers in diagnosis and man-
agement: part II: therapeutic management and follow-up. Circulation. 2003;108:
772-8.
3. Nienaber CA, Rousseau H, Eggebreecht H, Kische S, Fattori R, Rehders TC,
et al. Randomized comparison of strategies for type B aortic dissection: the IN-
vestigation of STEnt Grafts in Aortic Dissection (INSTEAD) trial. Circulation.
2009;120:2519-28.
4. Crawford ES, Mizrahi EM, Hess KR, Coselli JS, Safi HJ, Patel VM. The impact
of distal aortic perfusion and somatosensory evoked potential monitoring on pre-
vention of paraplegia after aortic aneurysm operation. J Thorac Cardiovasc Surg.
1988;95:357-67.
5. Kouchoukos NT, Wareing TH, Izumoto H, Klausing W, Abboud N. Elective hy-
pothermic cardiopulmonary bypass and circulatory arrest for spinal cord protec-
tion during operations on the thoracoabdominal aorta. J Thorac Cardiovasc Surg.
1990;99:659-64.
6. Brandt M, Hussel K, Walluscheck KP, B€oning A, Rahimi A, Cremer J. Early and
long-term results of replacement of the descending aorta. Eur J Vasc Endovasc
Surg. 2005;30:365-9.
7. Dake MD, Miller DC, Semba CP, Mitchell RS, Walker PJ, Liddell RP. Translu-
minal placement of endovascular stent-grafts for the treatment of descending tho-
racic aortic aneurysms. N Engl J Med. 1994;331:329-34.
8. Inoue KI, Iwase T, Sato M, Yoshida Y, Tanaka T, Kubota Y, et al. Clinical appli-
cation of transluminal endovascular graft placement for aortic aneurysms. Ann
Thorac Surg. 1997;63:522-8.
9. Mitchell RS,Miller DC, DakeMD, Semba CP,Moore KA, Sakai T. Thoracic aor-
tic aneurysm repair with an endovascular stent graft: the first generation. Ann
Thorac Surg. 1999;67:1971-4.
10. Mitchell RD, Dake MD, Semba CP, Fogarty TJ, Zarins CK, et al. Endovascular
stent graft repair of thoracic aortic aneurysms. J Thoracic Cardiovasc Surg. 1996;
111:1054-9.
11. Czermak BV, Waldenberger P, Perkmann R, Rieger M, Steingruber IE,
Mallouhi A, et al. Placement of endovascular stent grafts for emergency treat-
ment of acute disease of the descending thoracic aorta. AJR Am J Roentgenol.
2002;179:337-45.
12. Fattori R, Nienaber CA, Rousseau H, Beregi JP, Heijmen R,
Grabenwoger M, et al., Talent Thoracic Retrospective Registry. Results of
endovascular repair of the thoracic aorta with the Talent Thoracic stent graft:
the Talent Thoracic Retrospective Registry. J Thorac Cardiovasc Surg. 2006;
132:332-9.
13. Nienaber CA, Fattori R, Lund G, Dieckmann C, Wolf W, von Kodolitsch Y, et al.
Nonsurgical reconstruction of thoracic aortic dissection by stent-graft placement.
N Engl J Med. 1999;340:1539-45.ery c January 2013
Ehrlich et al Acquired Cardiovascular Disease14. Dake MD, Kato N, Mitchell RS, Semba CP, Razavi MK, Shimono T, et al. Endo-
vascular stent-graft placement for the treatment of acute aortic dissection. N Engl
J Med. 1999;340:1546-52.
15. Greenberg R. Treatment of aortic dissections with endovascular stent grafts.
Semin Vasc Surg. 2002;15:122-7.
16. Nienaber CA, Kische S, Zeller T, Rehders TC, Schneider H, Lorenzen B, et al.
Provisional extension to induce complete attachment after stent-graft placement
in type B aortic dissection: the PETTICOAT concept. J Endovasc Ther. 2006;13:
738-46.
17. Eggebrecht H, Nienaber CA, Neuh€auser M, Baumgart D, Kische S,
Schmermund A, et al. Endovascular stent-graft placement in aortic dissection:
a meta-analysis. Eur Heart J. 2006;27:489-98.
18. Kische S, Ehrlich MP, Nienaber CA, Rousseau H, Heijmen R, Piquet P, et al. En-
dovascular treatment of acute and chronic aortic dissection: midterm results from
the Talent Thoracic Retrospective Registry. J Thorac Cardiovasc Surg. 2009;138:
115-24.
19. Xiong J, Jiang B, Guo W, Wang SM, Tong XY. Endovascular stent graft place-
ment in patients with type B aortic dissection: a meta-analysis in China. J Thorac
Cardiovasc Surg. 2009;138:865-72.
20. Dialetto G, Covino FE, Scognamiglio G, Manduca S, Della Corte A, Giannolo B,
et al. Treatment of type B aortic dissection: endoluminal repair or conventional
medical therapy? Eur J Cardiothorac Surg. 2005;27:826-30.
21. White RA, Miller DC, Criado FJ, Dake MD, Diethrich EB, Greenberg RK, et al.,
Multidisciplinary Society for Vascular Surgery Outcomes Committee. Report onThe Journal of Thoracic and Cathe results of thoracic endovascular aortic repair for acute, complicated, type B
aortic dissection at 30 days and 1 year from a multidisciplinary subcommittee
of the Society for Vascular Surgery Outcomes Committee. J Vasc Surg. 2011;
53:1082-90.
22. Shu C, He H, Li QM, Li M, Jiang XH, Luo MY. Endovascular repair of compli-
cated acute type-B aortic dissection with stent graft: early and mid-term results.
Eur J Vasc Endovasc Surg. 2011;42:448-53.
23. Schoder M, Czerny M, Cejna M, Rand T, Stadler A, Sodeck GH, et al. Endovas-
cular repair of acute type B aortic dissection: long-term follow-up of true and
false lumen diameter changes. Ann Thorac Surg. 2007;83:1059-66.
24. Melissano G, Tshomba Y, Civilini E, Chiesa R. Disappointing results with a new
commercially available thoracic endograft. J Vasc Surg. 2004;39:124-30.
25. Kato M,Matsuda T, KanekoM, Kuratani T, Mizushima T, Seo Y, et al. Outcomes
of stent-graft treatment of false lumen in aortic dissection. Circulation. 1998;98:
II305-12.
26. Duebener LF, Lorenzen P, Richardt G, Misfeld M, N€otzold A, Hartmann F, et al.
Emergency endovascular stent-grafting for life-threatening acute type B aortic
dissections. Ann Thorac Surg. 2004;78:1261-7.
27. Taylor PR, Gaines PA, McGuinness CL, Cleveland TJ, Beard JD,
Cooper G, et al. Thoracic aortic stent grafts—early experience from two
centres using commercially available devices. Eur J Vasc Endovasc Surg.
2001;22:70-6.
28. Criado FJ, Clark NS, Barnatan MF. Stent graft repair in the aortic arch and de-
scending thoracic aorta: a 4-year experience. J Vasc Surg. 2002;36:1121-8.rdiovascular Surgery c Volume 145, Number 1 165
A
C
D
